Based on these findings, we conducted a feasibility study of PTE chemotherapy for previously treated advanced HER2-positive breast cancer, including an analysis of quality of life (QOL) and concomitant analysis of biomarkers such as sHER levels, PIK3CA gene mutation status and circulating Treg levels. The gene discussed is PIK3CA; the disease is breast carcinoma.